FindTrial
Sign In

Evaluation of the use of red propolis from Alagoas in improving the immunity of HIV patients undergoing treatment

Evaluation of the use of Brazilian red propolis in cd4 count and viral load of HIV patients undergoing antiretroviral treatment: randomized, double-blind, controlled clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3t9xx6j
Enrollment
Unknown
Registered
2025-11-25
Start date
2024-09-02
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD4 Lymphocyte Count

Interventions

This is a randomized, double-blind, placebo-controlled, two-arm clinical trial. Group I: Administration of 500 mg of dry extract of red propolis from Alagoas per day (supplement in capsules), divided

Sponsors

Centro Universitário Cesmac
Lead Sponsor
Centro Universitário Cesmac
Collaborator

Eligibility

Age
18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Volunteers diagnosed with human immunodeficiency virus (HIV); of both sexes; aged 18 to 59 years; undergoing antiretroviral therapy (ART); with undetectable viral load; and with a CD4 count below 350 cells/mL will be included

Exclusion criteria

Exclusion criteria: Pregnant women; homeless patients; patients allergic to propolis; hospitalized patients; people with mental illnesses that prevent participation in the research

Design outcomes

Primary

MeasureTime frame
An increase in CD4+ count is expected for values ??above 350 cells/mL—

Secondary

MeasureTime frame
Improvements are expected in the biochemical parameters of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and C-reactive protein (PCR)—

Countries

Brazil

Contacts

Public ContactJosé Marcos;Danielle Oliveira; Moura

Centro Universitário Cesmac;Centro Universitário Cesmac

jose_marcos_cbjr@hotmail.com;daniellemcz@hotmail.com+55 (82) 3215-5087;+55 (82 )32155021

Outcome results

None listed

Source: REBEC (via WHO ICTRP)